This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License
Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficile infection. This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School. The project was then licensed to Merck & Co., Inc. for further development and commercialization. A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:casNumber |
|
| dbo:fdaUniiCode |
|
| dbo:kegg |
|
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink | |
| dbp:atcPrefix |
|
| dbp:c |
|
| dbp:casNumber |
|
| dbp:chemspiderid |
|
| dbp:h |
|
| dbp:kegg |
|
| dbp:mabType |
|
| dbp:n |
|
| dbp:o |
|
| dbp:s |
|
| dbp:source |
|
| dbp:target |
|
| dbp:type |
|
| dbp:unii |
|
| dbp:wikiPageUsesTemplate | |
| dct:subject | |
| gold:hypernym | |
| rdf:type |
|
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:isPrimaryTopicOf | |
| is dbo:wikiPageRedirects of | |
| is dbo:wikiPageWikiLink of | |
| is foaf:primaryTopic of |